Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TROPION-Lung05: Datopotamab deruxtecan in Advanced or Metastatic NSCLC with Actionable Genomic Alterations
2024-511449-21-00Phase 2Completed
- Sponsor
- Daiichi Sankyo Co., Ltd.
- Start
- Mar 2021
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 7
01
Overview
Phase 2, open-label, single-arm trial of datopotamab deruxtecan in non-small cell lung cancer (NSCLC), sponsored by Daiichi Sankyo Co., Ltd. Started Mar 2021; status: completed.
02
Drugs
datopotamab deruxtecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-511449-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511449-21-00.